The company said total revenue for Q4 2023 decreased 4% from the same period a year earlier to $7.1 billion, and diluted earnings per share were $1.14, down from $1.30 a year earlier. The company cited lower Veklury and HIV sales as the reasons for the revenue decline.

1. 01

   The company said total revenue for Q4 2023 decreased 4% from the same period a year earlier to $7.1 billion, and diluted earnings per share were $1.14, down from $1.30 a year earlier. The company cited lower Veklury and HIV sales as the reasons for the revenue decline.

2. 02

   Gilead said full-year 2023 total revenue fell 1% from the prior year to $27.1 billion, while product sales excluding Veklury rose 7% to $24.7 billion. Biktarvy sales increased 14% to $11.8 billion.

3. 03

   The company reported operating cash flow of $8,006 million for the full year 2023 and free cash flow of $7,421 million. In Q4 2023, it paid cash dividends of $943 million and used $150 million to repurchase common stock.

4. 04

   Gilead provided full-year 2024 guidance for total product sales of $27.1 billion to $27.5 billion, diluted EPS of $5.15 to $5.55, and non-GAAP diluted EPS of $6.85 to $7.25. It also guided to product sales excluding Veklury of $25.8 billion to $26.2 billion.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.